Dorte Gyrd-Hansen

Dorte Gyrd-Hansen

Auto-generated profile, based on publicly available information

Dorte Gyrd-Hansen

Danish Centre for Health Economics (DaCHE), Department of Public Health, University of Southern Denmark , Odense, Denmark

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2005 in Health Economics
Verified
Journal Article
Closed access
PDF file
MBMickael Bech
Mickael Bech
DGDorte Gyrd-Hansen
Dorte Gyrd-Hansen

27 February 2003 in Health Economics
Verified
Journal Article
Closed access
PDF file
DGDorte Gyrd‐Hansen
Dorte Gyrd‐Hansen

1 January 2005 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Closed access
PDF file
EDEva Draborg
Eva Draborg
DGDorte Gyrd-Hansen
Dorte Gyrd-Hansen
PPPeter Bo Poulsen
Peter Bo Poulsen
MHMogens Horder
Mogens Horder
Objectives:Health Technology Assessment (HTA) is defined as a policy research approach that examines the short- and long-term social consequences of the application or use of technology. Internationally different institutions have translated this definition to local contexts. In Denmark, HTA is comprehensive with focus on four aspects of the problem in question (technology [clinical evidence], economy, patient, and organization). The objective of this study is to study how the application of HTA differs across leading countries and to study the extent to which Danish HTA reports differ from foreign HTAs.Methods:A sample of 433 HTA reports published in the period 1989–2002 by eleven leading institutions or agencies in Denmark and eight other countries were reviewed. We looked at the characteristics of the HTA with respect to focus on the four main aspects and the manner in which each aspect has been approached.Results:The study shows health technology procedures to be the most common type of health technology assessed in HTAs and literature review to be the most often used method of analysis. Policy recommendations are only present in approximately half of the HTA reports.Conclusions:In the HTAs one generally sees a great focus on the clinical aspect of health technologies, leaving the economic, the patient-related, and the organizational aspect much more unanalyzed. The Danish HTAs generally have a wider scope than HTAs produced in other countries and tend to focus more frequently on patient-related and organizational dimensions.

31 October 2013 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
GBGudrun Broberg
Gudrun Broberg
DGDorte Gyrd‐Hansen
Dorte Gyrd‐Hansen
JJJunmei Miao Jonasson
Junmei Miao Jonasson
MRMare‐Liis Ryd
Mare‐Liis Ryd
MHMikael Holtenman
Mikael Holtenman
BSBjörn Strander
Björn Strander

17 March 2015 in Neurology
Verified
Journal Article
Closed access
PDF file
DGDorte Gyrd-Hansen
Dorte Gyrd-Hansen
KOKim Rose Olsen
Kim Rose Olsen
KBKerstin Bollweg
Kerstin Bollweg
CKChristian Kronborg
Christian Kronborg
MEMartin Ebinger
Martin Ebinger
HAHeinrich J. Audebert
Heinrich J. Audebert
Objective: To analyze the cost-effectiveness of shorter delays to treatment and increased thrombolysis rate as shown in the PHANTOM-S (Prehospital Acute Neurological Treatment and Optimization of Medical Care in Stroke) Study. Methods: In addition to intermediate outcomes (time to thrombolysis) and treatment rates, we registered all resource consequences of the intervention. The analyzed treatment effects of the intervention were restricted to distribution of IV thrombolysis (IVT) administrations according to time intervals. Intermediate outcomes were extrapolated to final outcomes according to numbers needed to treat derived from pooled IVT trials and translated to gains in quality-adjusted life-years (QALYs). Results: The net annual cost of the Stroke Emergency Mobile (STEMO) prehospital stroke concept was €963,954. The higher frequency of IVT administrations per year (310 vs 225) and higher proportions of patients treated in the early time interval (within 90 minutes: 48.1% vs 37.4%; 91–180 minutes: 37.4% vs 50%; 181–270 minutes: 14.5% vs 12.8%) resulted in an annual expected health gain of avoidance of 18 cases of disability equaling 29.7 QALYs. This produced an incremental cost-effectiveness ratio of €32,456 per QALY. Conclusions: Depending on willingness-to-pay thresholds in societal perspectives, the STEMO prehospital stroke concept has the potential of providing a reasonable innovation even in health-economic dimensions.

1 January 2005 in PharmacoEconomics
Verified
Journal Article
Closed access
PDF file
DGDorte Gyrd-Hansen
Dorte Gyrd-Hansen